A Phase 3 interventional study of LDV/SOF and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 4 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.
Among the 174 studies testing ribavirin in Hepatitis C, this one is the 33rd largest by enrollment, is one of 20 that started in 2015, is one of 56 in phase 3, and was the 149th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 61 · Phase 3 64 · Phase 4 44
First in 1997; this study’s year is marked. 20 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 78 across the 174 interventional studies. Of the 158 that completed or were terminated, 79 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 174 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 22nd largest by enrollment of the 97 interventional ones that give a count, is one of 25 that started in 2015, is one of 35 in phase 3, and was the 76th registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 174 studies testing ribavirin in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LDV/SOF for 8 weeks (treatment-naive (TN))
Drug: LDV/SOF
LDV/SOF+RBV for 8 weeks (treatment-naive)
Drug: LDV/SOF · Drug: RBV
LDV/SOF for 12 weeks (treatment-naive)
Drug: LDV/SOF
LDV/SOF+RBV for 12 weeks (treatment-naive)
Drug: LDV/SOF · Drug: RBV
Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.
Drug: LDV/SOF · Drug: RBV
LDV/SOF for 12 weeks (treatment-experienced)
Drug: LDV/SOF
LDV/SOF+RBV for 12 weeks (treatment-experienced)
Drug: LDV/SOF · Drug: RBV
90/400 mg FDC tablet administered orally once daily
Also known as: Harvoni®, GS-5885/GS-7977
Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.
Time frame: Posttreatment Week 12
Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE)
Time frame: 12 weeks
Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
SVR4 and SVR24 were defined as HCV RNA \< LLOQ 4 and 24 weeks after the last dose of study drug, respectively.
Time frame: Posttreatment Weeks 4 and 24
Percentage of Participants With Overall Virologic Failure
Virologic failure was defined as * On-treatment virologic failure * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ, while on treatment (ie, breakthrough), * confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound), * HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse) * Relapse * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement
Time frame: Up to Posttreatment Week 24
Participants were enrolled in 4 sites in Egypt. The first participant was screened on 07 September 2015 and the last study visit was on 04 February 2017.
| Milestone | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) |
|---|---|---|---|---|---|---|---|
| Started | 43 | 42 | 43 | 42 | 36 | 38 | 11 |
| Completed | 41 | 38 | 41 | 40 | 34 | 37 | 11 |
| Not completed | 2 | 4 | 2 | 2 | 2 | 1 | 0 |
| Withdrew: Lack of efficacy | 2 | 4 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.
| percentage of participants | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) | 95.3 (84.2 to 99.4) | 90.5 (77.4 to 97.3) | 97.7 (87.7 to 99.9) | 97.6 (87.4 to 99.9) | 94.4 (81.3 to 99.3) | 100.0 (90.7 to 100.0) | 100.0 (71.5 to 100.0) |
| percentage of participants | LDV/SOF 8 Weeks | LDV/SOF + RBV 8 Weeks | LDV/SOF 12 Weeks | LDV/SOF + RBV 12 Weeks |
|---|---|---|---|---|
| Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE) | 0 | 0 | 0 | 1.1 |
SVR4 and SVR24 were defined as HCV RNA \< LLOQ 4 and 24 weeks after the last dose of study drug, respectively.
| percentage of participants | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) |
|---|---|---|---|---|---|---|---|
| SVR4 | 95.3 (84.2 to 99.4) | 95.2 (83.8 to 99.4) | 97.7 (87.7 to 99.9) | 97.6 (87.4 to 99.9) | 100.0 (90.3 to 100.0) | 100.0 (90.7 to 100.0) | 100.0 (71.5 to 100.0) |
| SVR24 | 95.3 (84.2 to 99.4) | 90.5 (77.4 to 97.3) | 97.7 (87.7 to 99.9) | 97.6 (87.4 to 99.9) | 94.4 (81.3 to 99.3) | 100.0 (90.7 to 100.0) | 100.0 (71.5 to 100.0) |
Virologic failure was defined as * On-treatment virologic failure * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ, while on treatment (ie, breakthrough), * confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound), * HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse) * Relapse * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement
| percentage of participants | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Overall Virologic Failure | 4.7 | 9.5 | 2.3 | 0.0 | 2.8 | 0.0 | 0.0 |
Collected over Up to 12 weeks + 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LDV/SOF 8 Weeks | — | 0/43 (0%) | 11/43 (25.6%) |
| LDV/SOF + RBV 8 Weeks | — | 0/42 (0%) | 15/42 (35.7%) |
| LDV/SOF 12 Weeks | — | 0/79 (0%) | 23/79 (29.1%) |
| LDV/SOF + RBV 12 Weeks | — | 3/91 (3.3%) | 41/91 (45.1%) |
| Event | LDV/SOF 8 Weeks | LDV/SOF + RBV 8 Weeks | LDV/SOF 12 Weeks | LDV/SOF + RBV 12 Weeks |
|---|---|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 0/43 | 0/42 | 0/79 | 2/91 |
| Chest PainGeneral disorders | 0/43 | 0/42 | 0/79 | 1/91 |
| Peripheral vascular disorderVascular disorders | 0/43 | 0/42 | 0/79 | 1/91 |
| Event | LDV/SOF 8 Weeks | LDV/SOF + RBV 8 Weeks | LDV/SOF 12 Weeks | LDV/SOF + RBV 12 Weeks |
|---|---|---|---|---|
| HeadacheNervous system disorders | 4/43 | 13/42 | 13/79 | 20/91 |
| FatigueGeneral disorders | 4/43 | 5/42 | 8/79 | 14/91 |
| AnaemiaBlood and lymphatic system disorders | 0/43 | 2/42 | 0/79 | 7/91 |
| ConstipationGastrointestinal disorders | 0/43 | 3/42 | 0/79 | 3/91 |
| DyspepsiaGastrointestinal disorders | 3/43 | 1/42 | 5/79 | 6/91 |
| BronchitisInfections and infestations | 3/43 | 1/42 | 3/79 | 2/91 |
| Abdominal pain upperGastrointestinal disorders | 0/43 | 2/42 | 0/79 | 6/91 |
| PyrexiaGeneral disorders | 1/43 | 1/42 | 1/79 | 5/91 |
Safety Analysis Set: participants who were randomized or enrolled and received at least 1 dose of study drug
| Age, Continuous(years) | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 53 ± 13.9 | 49 ± 12.2 | 49 ± 13.0 | 46 ± 12.1 | 49 ± 11.8 | 51 ± 10.1 | 48 ± 16.3 | 50.0 ± 12.5 |
| Sex: Female, Male(Participants) | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 18 | 20 | 21 | 20 | 4 | 13 | 3 | 99 |
| Male | 25 | 22 | 22 | 22 | 32 | 25 | 8 | 156 |
| Race/Ethnicity, Customized(Participants) | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|
| White | 43 | 42 | 43 | 42 | 36 | 38 | 11 | 255 |
| Race/Ethnicity, Customized(Participants) | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|
| Not Hispanic or Latino | 43 | 42 | 43 | 42 | 36 | 38 | 11 | 255 |
| IL28b Status(Participants) | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|
| CC | 12 | 5 | 11 | 9 | 8 | 8 | 0 | 53 |
| CT | 28 | 26 | 26 | 25 | 24 | 21 | 8 | 158 |
| TT | 3 | 11 | 6 | 8 | 7 | 9 | 3 | 47 |
| HCV RNA(log10 IU/mL)) | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 6.0 ± 0.64 | 5.6 ± 0.63 | 5.7 ± 0.69 | 5.8 ± 0.66 | 5.8 ± 1.10 | 5.8 ± 1.04 | 6.2 ± 0.59 | 5.8 ± 0.79 |
| HCV RNA Category(Participants) | LDV/SOF 8 wk TN (Cohort 1, Group 1) | LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2) | LDV/SOF 12 wk TN (Cohort 1, Group 3) | LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4) | LDV/SOF 12 wk TE (Cohort 3, Group 1) | LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2) | LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|
| < 800,000 IU/mL | 17 | 26 | 25 | 28 | 16 | 17 | 5 | 134 |
| ≥ 800,000 IU/mL | 26 | 16 | 18 | 14 | 20 | 21 | 6 | 121 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Sep 2015 to primary completion in Nov 2016, 14 months.
Results were first posted in Dec 2017, 1 year 1 month after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 14 months is close to that.
Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribavirin